Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Survival Benefit with Low-Dose Dexamethasone in Multiple Myeloma
Link ID 1576
Title Survival Benefit with Low-Dose Dexamethasone in Multiple Myeloma
Url http://www.medscape.com/viewarticle/567283?src=rss
Description Using low-dose dexamethasone with lenalinomide instead of high-dose dexamethasone in newly diagnosed multiple myeloma patients confers a significant survival advantage and has less toxicity. Medscape Medical News
Category Articles > Hematology-Oncology
Keywords
Date Dec 14, 2007
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. The Equivocally Amplified HER2 FISH Result on Breast Core Biopsy: Indications for Further Sampling D
  Might an equivocal HER2 amplification result from a breast core biopsy specimen be consistently representative of the HER2 status of the overall breast tumor? What are the testing implications?
American Journal of Clinical Pathology
Category:   Articles > Hematology-Oncology


2. New Therapeutic Options in CML and What They Mean for Patients: An Expert Interview With Dr. Jorge C
  In this Expert Interview from ASH 2007, Dr. Jorge Cortes discusses new and follow-up data from clinical trials of drug therapies for CML.
Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology


3. Maintaining Quality of Life in Patients With Refractory Metastatic Breast Cancer: An Expert Intervie
  Sequential vs combination chemotherapy? Bevacizumab? Ixabepilone? Dr. Martine Piccart offers her perspectives on treatment for metastatic breast cancer, with particular focus on quality of life.
Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology


4. EGFR Inhibitors in Advanced Stage NSCLC: Latest Principles and Practice
  Is there a new role for EGFR inhibitors in the treatment of lung cancer? In this expert column, Dr. Neil and Dr. Heist review the latest data. Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology


5. Latest FDA Labeling Changes for Erythropoiesis-Stimulating Agents
  ESAs are no longer indicated for use in cancer patients for chemotherapy-induced anemia if the intent of chemotherapy is to cure the patient. Medscape Medical News
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS